Technology Holding, LLC — Department of Defense SBIR Phase II: CBD192-007
Technology Holding, LLC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $541,247 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code CBD192-007 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $541,247
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- SBIR · Phase II
- Topic
- CBD192-007
- Solicitation
- 19.2
- NAICS
- —
- Place of performance
- UT
- Period
- 2021-09-15 → 2023-09-15
Description
The threat of organophosphate (OP) chemical warfare agents (CWA) to United States military personnel is a persistent problem due to the relative ease of manufacturing chemical threats compared to nuclear and biological agents. Human butyrylcholinesterase (HuBChE) has been identified as a probable bio-scavenger of OP CWAs that could be used to protect individuals that could be exposed to OP CWAs. The goal of this project is to generate a mammalian cell line capable of expressing human HuBChE in tetrameric form with appropriate human glycosylation patterns . To achieve this goal we will down select among our multiple HuBChE expressing cell lines and humanize the observed glycosylation patterns to match the plasma derived HuBChE standard. This approach will be evaluated to determine technical and economic applicability to full scale manufacturing.